Wealth Enhancement Advisory Services LLC increases stake in Hologic, Inc. (NASDAQ:HOLX)

VaselineAugust 26, 2024

0 4 minutes read

Hologic logo Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Hologic, Inc. (NASDAQ:HOLX – Free Report) by 11.3% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 4,804 shares of the medical equipment provider’s stock after purchasing an additional 487 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Hologic were worth $357,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Wedmont Private Capital boosted its holdings in Hologic by 6.0% in the second quarter. Wedmont Private Capital now owns 4,357 shares of the medical equipment provider’s stock valued at $338,000 after purchasing an additional 247 shares during the last quarter. Sequoia Financial Advisors LLC boosted its holdings in shares of Hologic by 2.3% in the second quarter. Sequoia Financial Advisors LLC now owns 7,215 shares of the medical equipment provider’s stock valued at $536,000 after purchasing an additional 165 shares during the period. Czech National Bank boosted its stake in Hologic by 7.7% in the second quarter. Czech National Bank now owns 44,473 shares of the medical equipment provider’s stock worth $3,302,000 after purchasing an additional 3,172 shares in the last quarter. SG Americas Securities LLC boosted its holdings in Hologic by 583.1% in the second quarter. SG Americas Securities LLC now owns 229,171 shares of the medical equipment provider’s stock worth $17,016,000 after acquiring an additional 195,623 shares during the period. Finally, QRG Capital Management Inc. grew its position in Hologic by 16.8% in the second quarter. QRG Capital Management Inc. now owns 89,162 shares of the medical equipment provider’s stock valued at $6,620,000 after purchasing an additional 12,845 shares in the last quarter. 94.73% of shares are currently owned by institutional investors and hedge funds.

Insider trading at Hologic

In other news, insider Brandon Schnittker sold 476 shares of the company’s stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total value of $39,560.36. Following the transaction, the insider now directly owns 3,735 shares of the company’s stock, valued at $310,415.85. The transaction was disclosed in a legal filing with the SEC, which is accessible via this link. In other Hologic news, insider Brandon Schnittker sold 476 shares of the company’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total value of $39,560.36. Following the transaction, the insider now directly owns 3,735 shares of the company’s stock, valued at approximately $310,415.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available on the SEC’s website. Also, CEO Stephen P. Macmillan sold 3,672 shares of the business’s stock in a transaction that occurred on Wednesday, July 17th. The shares were sold at an average price of $80.13, for a total value of $294,237.36. Following the completion of the sale, the chief executive officer now owns 1,157,562 shares of the company’s stock, valued at $92,755,443.06. The disclosure for this sale can be found here. Insiders have sold 18,280 shares of company stock worth $1,469,973 over the last 90 days. 1.75% of shares are currently held by corporate insiders.

Hologic price performance

Want more great investment ideas?

NASDAQ:HOLX opened at $80.25 on Friday. The stock has a 50-day moving average of $77.75 and a two-hundred-day moving average of $76.12. Hologic, Inc. has a 12-month low of $64.02 and a 12-month high of $84.67. The firm has a market cap of $18.73 billion, a P/E ratio of 40.94, a price-to-earnings-growth ratio of 2.64 and a beta of 0.99. The company has a current ratio of 3.99, a quick ratio of 3.29, and a debt-to-equity ratio of 0.51.

Hologic (NASDAQ:HOLX – Get Your Free Report ) last posted its quarterly earnings results on Monday, July 29th. The medical equipment provider reported $1.06 EPS for the quarter, topping the consensus estimate of $1.02 by $0.04. The firm had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $1 billion. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The company’s revenue for the quarter was up 2.7% year over year. In the same period last year, the company earned $0.93 per share. On average, analysts expect that Hologic, Inc. to post 4.08 earnings per share for the current fiscal year.

The Wall Street analyst weighs in

A number of brokerages have recently commented on HOLX. JPMorgan Chase & Co. raised their price objective on shares of Hologic from $91.00 to $95.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 30th. Evercore ISI boosted their target price on shares of Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a research report on Tuesday, July 30th. StockNews.com downgraded shares of Hologic from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 10th. Royal Bank of Canada reissued a “sector perform” rating and set a $82.00 target price on shares of Hologic in a research note on Friday, August 16th. Finally, Needham & Company LLC restated a “buy” rating and issued a $90.00 target price on shares of Hologic in a research note on Tuesday, July 30th. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $87.60, according to MarketBeat.

Check out our latest review on Hologic

About Hologic

(Free report)

Hologic, Inc develops, manufactures and supplies diagnostic products, medical imaging systems and surgical products for women’s health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgery and Skeletal Health. Offers Aptima molecular diagnostic tests to detect infectious microorganisms; Aptima viral load tests for hepatitis B virus, hepatitis C virus, human immunodeficiency virus, and human cytomegalovirus; Aptima Bacterial Vaginosis and Candida Vaginitis Tests for Vaginitis Diagnosis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 tests to detect SARS-CoV-2; ThinPrep System for cytology applications; and the rapid fetal fibronectin test that helps doctors assess the risk of preterm birth.